: Background: Barrett's esophagus (BE) is the precursor lesion for esophageal adenocarcinoma. While there is information on isolated somatic changes that occur during the progression of BE to dysplasia or cancer, the global changes in somatic gene expression underlying the transformation of normal esophageal mucosa to BE remain unknown. Hypothesis: BE is associated with altered gene expression patterns. Comparative gene expression studies using microarray analyses would identify BE-specific genes that provide insight into the molecular basis of BE. Our preliminary data indicate an overactive Wnt/beta-catenin pathway in BE.
Specific Aim #1 : To identify the specific gene expression pattern for Barrett's esophagus. a) Recruit individuals from three well-defined phenotypically distinct cohorts: patients with BE, patients with GERD and no BE, and volunteers with no GERD or BE. b) Obtain endoscopically and histologically well-defined tissue classes from cohorts identified in SA#1.a.; these tissue classes are BE, normal esophageal, gastric, duodenal, and colonic epithelia. c) Use laser microdissection to capture glandular tissue. d) Use microarray analysis to compare the global gene expression of BE to several control tissues obtained from the three cohorts (SA# 1.a and 1.b).
Specific Aim #2 : To identify novel gene(s) and/or pathways in the pathogenesis of Barrett's esophagus. a) Apply the gene expression data to metabolic and/or physiological pathways with sample size calculation geered toward the Wnt/beta-catenin pathway. b) Use quantitative RT-PCR to confirm the altered expression of BE-specific genes. Methods: We will obtain endoscopic biopsies from esophageal, gastric, duodenal, and colonic tissue from 30 patients (10 with BE, 10 with GERD w/o BE, and 10 with no GERD or BE). We will conduct microarray assays using RNA extracted from these specimens on Human Genome Affymetrix (HG- 133U) Set GeneChip(r). The data will be analyzed to identify downregulated and upregulated genes that are unique to BE. Pathway surveys will be conducted with confirmation of these genes using RT-Q-PCR. We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21DK067366-02
Application #
7098846
Study Section
Clinical and Integrative Gastrointestinal Pathobiology Study Section (CIGP)
Program Officer
Hamilton, Frank A
Project Start
2005-08-01
Project End
2007-12-31
Budget Start
2006-08-01
Budget End
2007-12-31
Support Year
2
Fiscal Year
2006
Total Cost
$146,475
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Dore, Maria Pina; Lu, Hong; Graham, David Y (2016) Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 65:870-8
Graham, David Y (2016) Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter 21:85-90
Graham, David Y (2015) Editorial--Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants. Helicobacter 20:321-5
Trespalacios, Alba A; Rimbara, Emiko; Otero, William et al. (2015) Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagn Microbiol Infect Dis 81:251-5
Graham, David Y; Lee, Sun-Young (2015) How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am 44:537-63
Graham, D Y; Lu, H (2015) Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance. Aliment Pharmacol Ther 41:1220-1
Zhang, Wei; Chen, Qi; Liang, Xiao et al. (2015) Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 64:1715-20
Graham, David Y (2015) Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med 30:133-9
Graham, David Y (2015) Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148:719-31.e3
Hanada, Katsuhiro; Uchida, Tomohisa; Tsukamoto, Yoshiyuki et al. (2014) Helicobacter pylori infection introduces DNA double-strand breaks in host cells. Infect Immun 82:4182-9

Showing the most recent 10 out of 45 publications